Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. She was a patient at the DMC Sinai-Grace Hospital in Detroit.

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. She was a patient at the DMC Sinai-Grace Hospital in Detroit. 

News | Cardiac Rehabilitation | January 15, 2020

January 15, 2020 – Too few people covered by Medicare participated in outpatient cardiac rehabilitation after a...

This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial.

This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial. 

News | Heart Valve Technology | January 13, 2020

January 13, 2020 — The U.S. Food and Drug Administration (FDA) has approved clinical trial that will compare the...

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor

January 2, 2020 — In early December 2019, leaders of the European...

Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019

Environmental and lifestyle issues were popular this year, with pick up from both...

Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent...

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

News | Heart Valve Technology | November 26, 2019 | Dave Fornell, Editor

November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a...

News | Cardiovascular Clinical Studies | November 26, 2019

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have...

cardiac arrest cath lab
News | AHA | November 21, 2019

November 21, 2019 — People who experience cardiac...

The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment...

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session.

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session. Photo by AHA/Phil McCarten

Blog | Heart Failure | November 21, 2019

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including...

Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety...

heart disease
News | AHA | November 20, 2019

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people...

 Assorted pastries
News | AHA | November 20, 2019

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories...

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff 

Feature | AHA | November 19, 2019

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of...

The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at...

Overlay Init